The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
The Life Raft Group is committed to ensuring your GIST journey is as manageable as possible. We want to ensure that we expand our resources in order to help patients stay on their treatment longer by helping them to manage their side effects.
The Life Raft Group is pleased to announce the official establishment of our Regional Patient Registry, a partnership with Latin America, which will collect medical history and treatment information from more than 600 GIST patients who are represented by Fundación GIST Mexico, Fundación GIST Chile, and Pontificia Universidad Católica de Chile.
International collaborations accelerate patient advocacy and affect policy changes and treatment protocols On May 7th, representatives from Colombia, Chile, Mexico, and The Life Raft Group assembled for the annual Salud con Datos [...]
On September 6th, Executive Director, Norman Scherzer and I attended the New Horizons GIST meeting in Vienna, Austria. Forty-three delegates, including GIST experts, advocacy groups, and patients/caregivers from 18 countries, gathered to share valuable [...]
On April 6th, 2018, Executive Director, Norman Scherzer; Data Analyst, Jerry Call; Real World Evidence Scientist, Yu Wang, and Patient Registry Director, Denisse Montoya, of The Life Raft Group, were invited to present at [...]
